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mutation. The sensitivity and specificity of Cobas 4800 BRAF V600 in vitro diag-
nostic test is excessively high to detect the V600 mutation. In the BRIM-3 study, 
vemurafenib showed improved PFS and OS in patients carrying BRAF mutation. 
Our aim is to analyze the vemurafenib international and local real-life survival data 
of the patients treated in the National Institute of Oncology, in case of individual 
reimbursement application. Methods: We retrospectively assessed the single 
centre Hungarian real-life survival data from 2012 to May 2015. We compared the 
outcome of the Hungarian and the French real-life and BRIM-3 data. Results: In 
the selection of the patient group suitable for BRAFi therapy, we carried out 277 
BRAF mutation analysis with Cobas test during the given period. 148 cases were 
wide type, the mutation rate was 46,57% with 129 mutant cases. In Hungary, BRAFi 
therapy is reimbursed, only on the basis of individual reimbursement application. 36 
MM patients were enrolled, with median age of 53,5 years. The median PFS reached 
5,4 months, the OS reached 12,3 months. In the previously published French single 
centre trial, in temporary authorisation program, the median PFS was 3,6 months, 
the median OS was 7,5 months. The BRIM-3 study demonstrated mPFS 6,9 months 
and OS 13,6 months. ConClusions: The detection of BRAF mutation is essential 
in the therapeutic strategy of metastatic melanoma patients. The Cobas 4800 BRAF 
test allows a more exact selection of the patient group to be treated by BRAFi. 
Our single centre OS data are close to BRIM3 clinical trial data. In case of previous 
vemurafenib therapy started in appropriate treatment line, further improvement 
can be expected in survival results.
CANCER – Cost Studies
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ThE BudgET ImPACT of dENoSumAB IN ThE TREATmENT of gIANT CEll 
TumoR of ThE BoNE (gCTB) IN BElgIum
Cristino J1, Fikkert V2, Flament A2, Vingerhoedt S2, Qian Y3
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Belgium, Brussels, Belgium, 3Amgen Inc., 
Thousand Oaks, CA, USA
objeCtives: To estimate the budget impact in Belgium of denosumab (120 mg) 
in the treatment of GCTB, an extremely rare, locally aggressive benign tumor 
often leading to severe destruction of bone and extension into the surround-
ing soft tissues. Methods: A budget impact model was developed, combining 
epidemiological data, proportions of resectable and unresectable GCTB disease, 
and eligibility for treatment with denosumab. Evidence collected in clinical tri-
als is used to estimate the denosumab clinical effect. Publicly available costs of 
the relevant surgical procedures and the actual cost for denosumab 120 mg from 
payer perspective are considered. The clinical effect of denosumab in delaying 
or downgrading invasive surgeries is estimated by comparing the surgical pro-
cedures planned at trial entry and the procedures actually performed during the 
trial. To calculate the savings in surgical procedures, the downgrade in planned 
procedures and only 50% of the avoided procedures in the trial period were con-
sidered. Resource use associated with the surgical procedures included the need 
for rehabilitation and re-hospitalizations due to complications. Savings were only 
applied to patients with resectable tumors. The model does not take into account 
the full clinical benefit of denosumab including decrease in disease progression 
in patients who have not undergone surgery. The time horizon considered was 3 
years. Results: Denosumab is expected to be provided to 32, 42 and 53 patients in 
year 1, 2 and 3, respectively. 550,940 euros of total drug expenditure are expected. 
Savings were estimated at 409,372 euros, the majority of which was attributable 
to fewer and less severesurgical procedures. The impact of denosumab on the 
overall health care budget is 141,568 euros over three years. ConClusions: The 
introduction of denosumab in the treatment of GCTB has a manageable budget 
impact in Belgium. Seventy four percent of the denosumab expenditure is off-set 
thanks to its clinical benefit.
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BudgET ImPACT ANAlySIS of dASATINIB AS A SECoNd-lINE ThERAPy IN 
PATIENTS wITh ChRoNIC myElogENouS lEukEmIA (Cml) IN ThE RuSSIAN 
fEdERATIoN
Kulikov A, Yagudina R, Protsenko MV
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: CML is among seven nosologies included in the federal program 
for supply of medicines to patients with rare diseases in the Russian Federation. 
Currently only first-generation tyrosine kinase inhibitor - imatinib is available to 
CML patients within this program. However from 25% to 30% of CML patients in 
Russia have intolerance or develop resistance to imatinib and require second line 
therapy with dasatinib or nilotinib. Methods: This study includes budget impact 
analysis (BIA) for dasatinib as a second-line CML therapy. Only direct pharmaco-
therapy costs were considered. Annual treatment cost of dasatinib amounts to 
1,720,111 rubles (28,365 € ) for chronic phase. Time horizon was set at 1 year. In 
the baseline scenario it was assumed that 100% of the imatinib-resistant patients 
are treated with high-dose imatinib in frame of the federal “seven nosologies” 
program. In the future scenario upon dasatinib inclusion into aforementioned 
program the percentage of patients that would be possible to switch from high-
dose imatinib to dasatinib without increase of the total national CML budget was 
calculated. Also annual economic impact of providing dasatinib as a second-line 
therapy to 100% of the eligible patients was estimated. Assumptions regarding 
adherence to treatment of patients diagnosed with CML and actual medica-
tion consumption rate were included into analysis. Results: Budget impact 
analysis was carried out for a total population of 7100 patients according to the 
national CML registry in 2015. Centralized purchase of dasatinib in frame of the 
federal program could save 463 mln rubles (7,7 mln € ) or 10% of the actual total 
CML budget in Russia. ConClusions: With consideration for actual dasatinib 
use within regional drug provision programs it was demonstrated that 100% of 
the imatinib-resistant and intolerant patients can be provided with dasatinib 
using Kaplan-Meier estimates. Additional data from the Dutch Comprehensive 
Cancer Centres (stage IV only) were used to compare survival outcomes in two 
time periods (2003-2011 versus 2012-2015). Results: From 2012-2015, 1259 patients 
received systemic treatment (median follow-up 12.6 months; data cut-off March 
09, 2015). The most frequently prescribed treatments were ipilimumab (29%) and 
vemurafenib (29%), followed by trial-based treatments (27%), chemotherapy (11%), 
and dabrafenib (4%). Vemurafenib was the most frequently applied treatment in the 
first line (41%), ipilimumab in the second line (56%), and trial-based treatments in 
the third and fourth line (41% and 63%, respectively). The median TTNT was 5.4, 4.7 
and 4.3 months in the first, second, and third line, respectively. The median OS was 
9.6 months (IQR 4.6-18.6) and the one-year survival was 41% (unresectable stage IIIc 
[n= 33]: median OS 32.8 months, one-year survival 71%; stage IV [n= 1226]: median 
OS 9.3 months, one-year survival 40%). In contrast, survival outcomes of stage IV 
melanoma were much lower in the period before the introduction of new drugs 
(2003-2011: median OS 6.8 months, one-year OS 33%). ConClusions: Melanoma 
survival has improved since the introduction of new drugs for advanced melanoma. 
The survival gain shown in pivotal trials was also observed in real-world clinical 
practice in The Netherlands.
PCN65
moRTAlITy TRENdS IN CANCERS: A NEw modEl To VISuAlISE ThE 
CoNTRIBuTIoN of SPECIfIC dISEASES, CohoRTS ANd CodINg ChANgES To 
oVERAll moRTAlITy ImPRoVEmENT
Martin C, Martin A
Crystallise Ltd., London, UK
objeCtives: Identifying the drivers of trends in mortality for disease classes is 
challenging. We used the Requiem model to visualise trends by gender and age 
in 3-D format to identify cohort and other effects in specific cancers. Methods: 
The Requiem model analysed and smoothed ONS mortality statistics for England 
and Wales from 1970 to 2013 by single year of age and gender. Disease codes were 
mapped at 4-digit level from ICD-8 to ICD-10 by medical modellers. An analysis 
was run for total cancer mortality and individual malignant diseases within that 
category. Outputs were displayed in multiple formats, including 3-D images of cen-
tral mortality and deaths by age over time, and heat maps of absolute mortality 
improvement per disease and the component each disease contributed to all-cause 
mortality trends. Results: Cancer mortality increased from 1970 to 1990s and has 
since fallen by up to 4% per year, accounting for a 1-2% of absolute improvement 
in all-cause mortality, and with evidence from heat maps for cohort effects. Most 
cancers showed increasing mortality rates to the 1990s, which have now declined. 
This is seen particularly in men in lung cancer, which saw up to 10% improvement 
per year in mortality, in breast cancer in women, with a peak in the 1980s and up 
to 20% annual improvement since then, and in colon cancer in both genders, with 
a 5-10% annual improvement in mortality per year. Hodgkin’s lymphoma mor-
tality has decreased steadily in both genders, while non-Hodgkin’s mortality has 
increased in the over 50s. Mortality continues to worsen for liver, kidney and CNS 
cancers. Pancreatic cancer has shown little change in mortality since 1970 in either 
gender. ConClusions: The Requiem model 3-D visualisation facilitates the under-
standing of trends in mortality for different cancers, and shows the impact of cohort 
effects and risk factors such as smoking and alcohol.
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EVAluATIoN of ‘REAl-woRld’ IPIlImumAB dATA IN IRElANd
McCullagh LM1, Adams R1, Barry M1, Schmitz S2, Walsh C3
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 
3University of Limerick, Limerick, Ireland
objeCtives: Ipilimumab is licensed for the treatment of adults with advanced (unre-
sectable or metastatic) malignant melanoma. It was approved for reimbursement in 
Ireland in 2012, through the Oncology Drug Management System (ODMS). The ODMS 
was introduced by the National Cancer Control programme in July 2012. The scheme 
allows direct hospital reimbursement for approved high cost anti-cancer drugs 
for individual patients. Drugs must be prescribed for approved indications accord-
ing to license informed protocols. The online based system is designed to collect 
information from hospitals (26 nationally) in relation to patient demographic data, 
cancer drug use and spending. This data is maintained by the payer (Primary Care 
Reimbursement Service (PCRS)). The objective of this study is to examine this real 
world data of patients treated with ipilimumab. Methods: The PCRS extracted data 
on all patients who had received ≥ 1 dose of ipilimumab ( June 2012 - May 2015) in the 
public hospital setting through the ODMS. Patient data included patient demograph-
ics, the quantity of ipilimumab supplied and the reimbursement claim data. The 
National Centre for Pharmacoeconomics analysed this anonymised data. Kaplan-
Meier survival curves were constructed using the Tierney et al methodology. Survival 
data was extrapolated using the Hoyle and Henley methodology. Results: A total 
of 205 patients who had received ≥ 1 dose ipilimumab over the period of analysis 
were identified. The mean age of the cohort was 60.4 years (SD ±14) and 58.5% were 
male. All 4 cycles of ipilimumab were received by 59% of patients. Seven patients 
were re-treated with the drug. Empirical and extrapolated real world survival data 
were compared to clinical trial evidence. ConClusions: The analysis provides 
real world survival outcomes for patients with advanced malignant melanoma 
treated with ipilimumab in Ireland. Examination of this evidence is prudent in 
advance of the launch of the PD1 inhibitors for malignant melanoma.
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RETRoSPECTIVE ComPARISoN of REAl-lIfE SuRVIVAl dATA fRom SINglE 
CENTRE TRIAlS - ThE ClINICAl ouTComE of VEmuRAfENIB ThERAPy IN 
mETASTATIC mElANomA PATIENTS
Porneczy E1, Czirbesz K1, Toth E1, Liszkay G1, Boncz I2
1National Institute of Oncology, Budapest, Hungary, 2University of Pecs, Pecs, Hungary
objeCtives: The selection of the MM patient group, eligible for BRAFi therapy is 
based on the molecular pathologic diagnostics of the BRAF V600 gain-of-function 
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diversity of the health professionals and the basic scenario. The costliest scenarios 
were the one implementing HPV DNA testing which did not provide further partici-
pation despite a high cost and the one based on P4P incentives towards GP, although 
it allows high participation rates. ConClusions: Using a comprehensive BIM, we 
show that full coverage of OS might be the most cost-effective way to implement it, 
although practical and financial issues might favour other scenarios that may be 
more balanced regarding the distribution of costs between stakeholders or may be 
more easily implemented and accepted by health professionals.
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BudgET ImPACT ANAlySIS oR PhARmACologICAl ThERAPy of ChRoNIC 
myEloId lEukEmIA (Cml) wITh NIloTINIB AS ThE SECoNd-lINE TREATmENT 
IN RuSSIAN fEdERATIoN
Serpik VG, Yagudina R
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Medicine supply of patients with CML is provided by means of federal state reim-
bursement program (FSRP) of high-cost nosologies and by regional budgets. Now, 
the reimbursement list of high-cost drugs includes only first generation tyros-
ine kinase inhibitor (TKI) – imatinib. However, there is a problem with access of 
patients with CML to second generation TKI because regional budgets are limited. 
Therefore, it’s important to provide pharmacoeconomic assessment of including 
second generation TKI into FSRP.objeCtives: To provide budget impact analysis 
(BIA) of including second generation TKI (nilotinib) into reimbursement list of high-
cost drugs of FSRP for second line treatment of patients with CML. Methods: BIA, 
as a part of this healtheconomic research was developed on the basis of decision 
tree and Markov model.The perspective of the study was FSRP of high-cost drugs, 
so direct costs for imatinib and nilotinib were considered.Real consumption of 
medicine was used.Tender prices of FSRP for imatinib and regional tender prices 
for nilotinib were used. Exchange rate 1Euro = 50Rub. Results: Annual cost per 
patient for imatinib for the first line CML patient in chronic phase was 6336Euro, 
while patients in accelerated phase and the second line treatment patients needed 
high dose imatinib treatment that costs 12672Euro.Annual cost per patient for 
nilotinib was 35040Euro.Total expenditures for first line treatment of CML with 
imatinib and the second line treatment with nilotinib for all CML patients were 
82,2 mln Euro.FSRP budget for CML in 2014 was 46 mln Euro, regional expenditures 
for the second line treatment with second generation TI of CML were above 44 
mln Euro.Therefore, including of nilotinib into FSRP leads to budget increase, but 
doesn’t exceed total current expenditures for CML of 90 mln Euro. ConClusions: 
Inclusion of nilotinib into FSRP does not exceed total current expenditures for CML 
and may improve patient access for effective treatment.
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PhARmACoECoNomIC ANAlySIS of ThE uSE of EVERolImuS ComPAREd To 
AxITINIB IN SECoNd lINE ThERAPy of PATIENTS wITh mETASTATIC RENAl 
CEll CARCINomA
Kolbin A1, Frolov M2, Kurylev A1, Balykina Y3, Proskurin M3
1First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, 2Volgograd State 
Medical University, Volgograd, Russia, 3Saint Petersburg State University, Saint Petersburg, Russia
objeCtives: The aim of the study was to conduct a health economic evaluation 
of using everolimus and axitinib in patients with metastatic renal cell carcinoma 
(mRCC). Methods: Cost-effectiveness analysis, budget impact analysis and sensi-
tivity analysis were performed. Progression-free survival and overall survival were 
included into the model as the effectiveness criteria. Decision tree model with Markov 
cycles was used. All direct costs were calculated from the healthcare system perspec-
tive. Stability of results to changes of external factors was evaluated by performing a 
probabilistic sensitivity analysis. Results: An analysis showed that the use of everoli-
mus was by 35% less expensive than the use of axitinib. At the same time a decrease in 
the probability of adverse event occurrence for everolimus, as well as an increase in the 
duration of overall survival by 27% were observed. The total cost per patient amounted 
to 1,686,463 RUB and 2,283,237 RUB when using everolimus and axitinib respectively. 
Compared to axitinib therapy, everolimus therapy is less expensive and at the same 
time, is more effective, i.e. it is dominant in relation to axitinib when considering such 
effectiveness criteria as overall survival and progression-free survival. The results of 
sensitivity analysis confirmed results of the baseline scenario regarding the economic 
feasibility of everolimus usage. The results of the budget impact analysis showed 
potential savings of budget finance in case of using everolimus, which provides an 
opportunity to treat additional patients with mRCC with no additional expenditures on 
the part of health care system. ConClusions: Everolimus showed a longer duration 
of overall survival in patients with mRCC after ineffectiveness of the first-line therapy. 
Moreover, everolimus therapy was less costly compared to axitinib therapy. Thus, the 
results of the study showed that the use of everolimus is a cost-effective strategy, as 
it is characterized by greater efficiency and lower costs.
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CoST ANAlySIS IN ImPlEmENTINg RITuxImAB foR NoN-hodgkINS 
lymPhomA - INTRAVENouSly ANd SuBCuTANEouSly - IN PATIENTS wITh 
SoCIAl CoVERAgE IN lATAm
Renati L1, Najun Dubos L2
1FASTA Unversity, Mar Del Plata, Argentina, 2Roche Argentina, Buenos Aires, Argentina
objeCtives: To compare cost of rituximab both Intravascular and subcutaneous for 
the treatment of NHL in patients within the social security and retiree segment And 
leaving in rural areas of ARGENTINA. Methods: Insurance given by two main sec-
tors were analysed. IOMA covers 157.741 beneficiaries while PAMI covers 215.118 . 1st 
line and 2nd line full treatments were calculated. As RTX cost is equivalent between 
formulations, we calculated the modules of the treatment including medical fee, 
materials etc. taking into account the IOMA value of USD 140.20 and PAMI one of 
USD 127.12 and the time of treatment in minutes we estimate the savings with the 
SC formulation. Results: IOMA Cost taking into account the consumption of time 
is around USD 1.190, 78 for the first line treatment and USD 899, 66 for the second 
as a second line treatment without increase of the total national CML budget 
in 2014.
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RAdIo-223 IN ThE TREATmENT of mETASTATIC CASTRATIoN RESISTANT 
PRoSTATE CANCER wITh BoNE mETASTASES: BudgET ImPACT ANAlySIS of 
ThE NATIoNAl hEAlTh SERVICE
Di Matteo S1, Valentino MC1, Bruno GM1, Colombo GL2
1S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy, 2University of Pavia, Milan, 
Italy
objeCtives: Castration resistant prostate cancer with bone metastases (mCRPC) is a 
common condition associated with high medical and indirect healthcare costs. Purpose 
of this analysis is to estimate the economic consequences of Radio-223 dichloride in the 
treatment of prostate cancer with definition of a Budget Impact Analysis (BIA) from the 
perspective of the National Health Service (NHS). Methods: Budget Impact analysis 
was carried to quantify the impact on the Italian National Health Service, in terms of 
costs of treatment given to the castration resistant prostate cancer (mCRPC), and as a 
result of the introduction of Radio-223 dichloride. In the assessment it was assumed 
that all the formulations present the same effect, ie that they present the same prob-
ability of efficacy in the treatment of metastatic castration resistant prostate cancer. The 
calculated values were applied to a population with mCRPC estimated the first year by 
about 4,009 people. Results: Considering the cost of the drug, the costs of administra-
tion, the cost of each adverse event, the total costs of each therapy, Radio-223 dichloride 
appears to have a lower cost than Abiraterone in both setting of patients in the first 
and second line treatment, lower than Enzalutamide in post-docetaxel population. The 
total costs were as follows: Radio-223 dichloride € 24,662.13; Abiraterone pre-Docetaxel € 
54,112.25, € 28,490.63 Abitaterone post-docetaxel, Cabazitaxel € 26,995.20, Enzalutamide 
€ 30,885.55 and finally Docetaxel € 4,574.69. Overall, looking at the scenario of the 1st 
and 2nd line following the introduction of Radio-223 dichloride it would generate sav-
ings of € 1,467,994 the first year, € 3,545,090 in the second year and finally € 7,660,642 in 
the third year. ConClusions: Treatment with Radio-223 dichloride turns out to have 
a favorable impact on the budget and appears to be the less expensive compared to 
other therapeutic strategies used in mCRPC in Italy.
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ECoNomIC ImPACT of ThE dETECTIoN of mEdICATIoN ERRoRS IN 
oNCologICAl PATIENTS wITh AfEBRIlE NEuTRoPENIA IN A CANCER 
hoSPITAl
Hernández Martínez JF1, Morales Perez M1, Colín Gómez DP1, Paredes García P1,  
Toledo Vigueras I1, Gutierrez García M2, Toledo Vigueras E1, Patricio Irineo F1,  
Sánchez Ródriguez I1
1Centro Oncológico Estatal, ISSEMyM, Toluca, Mexico, 2HS Estudios Farmacoeconómicos S.A. de 
C.V, Mexico City, Mexico
objeCtives: To determine the avoided cost derived from the opportune interven-
tion of the pharmacist before to the administration of schemes of chemotherapy 
avoiding medication errors (EM). Methods: A transverse analysis of EM’s record 
was realized (classification in accordance with Otero et al., 2000) in solid tumors, 
that evaluate the Clinical Pharmacy Service (CPS), in a period from November 2014 
to April 2015. The intention was to identify the cases of afebrile neutropenia (AN) 
before the application of the scheme of chemotherapy. The cost that had been gen-
erated by the handling of an uncomplicated febrile neutropenia were estimated, 
in accordance with the international recommendations of clinical practice, direct 
medical costs were considered: medicines (institutional catalog of prices), medical 
consultation, laboratory study and hospitalization from Official Federation Journal 
and groups related to the diagnosis IMSS 2015. Results: It was identified a whole 
of 365 (30 %) EM of 1195 pharmacotherapy follow-up, We found 22 patients who had 
AN, with an age average of 52 years, of which 54 % were women, this means 8% of 
total medication errors; 100 % of these errors of this patients group was a category 
“B” the error did not get the patient. The saving by the pharmaceutical interven-
tions was estimated in $80,228(USD), minus the cost of the prophylactic treatment 
after intervention ($13,624). The whole saving was $66,604, so that monthly average 
cost saved by CPS was of $11,101; there are 6 clinical pharmacists, that individu-
ally saved $1,850 monthly. The patients were rescheduled for their application of 
chemotherapy until cure the neutropenia, a prophylaxis was given for the subse-
quent cycles. ConClusions: The opportune intervention of the pharmacist in the 
identification and resolution of medication errors not only represents a clinical 
benefit in the safety of the patient, also is a monetary saving to the institution.
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whAT IS ThE moST CoST-EffECTIVE wAy To SET-uP oRgANISEd CERVICAl 
CANCER SCREENINg IN fRANCE? A BudgET ImPACT ANAlySIS
Massetti M1, Leleu H1, De Bels F2, Barre S2
1PUBLIC HEALTH EXPERTISE, Paris, France, 2French Cancer Institut, Boulogne, France
objeCtives: Accordingly to the third Cancer plan, organized screening (OS) of cervical 
cancer among women aged 25-65 should be implemented in the forthcoming years in 
France. The most cost-effective way to implement OS in the French health care system 
in regard of this objective is yet to be determined. Methods: A budget impact model 
(BIM) was developed in collaboration with the French National Institute of Cancer 
(INCa) and an expert board involving clinical experts and stakeholder representa-
tives (social security, ministry of health, patients and professionals). Time horizon of 
the analysis is three years. Five plausible scenarios aimed towards the whole non-
participating population were assessed in the model. Those were derived from a 
basic scenario consisting of a mailed invitation followed by a mailed recall to which 
were added HPV DNA testing for women over 35, self-sampling kits sent to women 
over 35, pay for performance (P4P) incentives allocated to general practitioners (GP) 
whose eligible patients become participant, diversification of health professionals 
performing the sampling and full coverage of the screening by the statutory health 
insurance. Results: The “full coverage scenario” is the most cost-effective, followed 
by the scenario with self-sampling kits sent to women, the scenario with increased 
